Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med;
390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38084760
2.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med;
389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37272512
3.
How I treat multiple myeloma in geriatric patients.
Blood;
143(3): 224-232, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36693134
4.
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.
Blood;
2024 Feb 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38394666
5.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood;
2024 Apr 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38643494
6.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood;
141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36375118
7.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol;
25(5): e205-e216, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38697166
8.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood;
139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35171994
9.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood;
139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35511184
10.
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.
Haematologica;
109(2): 604-616, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37584290
11.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica;
2024 Feb 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38385280
12.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica;
2024 Mar 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38546696
13.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica;
2024 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38299578
14.
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
Eur J Haematol;
2024 May 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38722078
15.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol;
2024 Apr 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38654611
16.
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Eur J Haematol;
2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38693052
17.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Eur J Haematol;
2024 May 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38712850
18.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol;
20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38197267
19.
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Br J Haematol;
201(6): 1103-1115, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36974007
20.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood;
138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33827114